Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,870 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sexually Transmitted Diseases, Viral Clear all
Completed Not applicable Interventional

Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV

NCT00602758
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
Motivational interviewing with cognitive behavioral therapy, Modified directly observed therapy
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 2 Interventional

Immune Restoration by Lipoic Acid in AIDS

NCT00033176
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
San Francisco, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family-based HIV Prevention for Adolescent Girls

NCT00243126
View directory record Official record
Conditions
HIV Infections
Interventions
Family-Based Risk Reduction Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 19 Years · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 2 Interventional

Acupuncture/Moxibustion for Peripheral Neuropathy in HIV

NCT00317291
View directory record Official record
Conditions
Peripheral Neuropathies, HIV Infections
Interventions
Acupuncture/Moxibustion, Sham acupuncture/Placebo moxibustion
Procedure · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Not applicable Interventional

A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC

NCT00000718
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

NCT00001090
View directory record Official record
Conditions
HIV Infections
Interventions
APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
4
States / cities
Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 4 Interventional Results available

Valganciclovir to Reduce T Cell Activation in HIV Infection

NCT00264290
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus Infections
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 2Phase 3 Interventional

Vitamin D Supplementation in HIV

NCT01475890
View directory record Official record
Conditions
HIV-infection/Aids
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 24 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 14, 2026, 7:43 PM EDT
Not listed Phase 3 Interventional

Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs

NCT00006397
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Stavudine, Didanosine
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Fort Lauderdale, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 7:43 PM EDT
Completed No phase listed Observational

Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)

NCT03572335
View directory record Official record
Conditions
HIV Infections, Pulmonary Disease
Interventions
PFT's (pulmonary function testing)
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 14, 2026, 7:43 PM EDT
Completed No phase listed Observational

Instacare - Rapid ART Initiation Among Persons With HIV and Out of Care

NCT04240691
View directory record Official record
Conditions
Hiv, HIV Infections
Interventions
60-Minutes-For-Health, Time-and-Attention Control Session
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

NCT00000854
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Nandrolone decanoate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 14, 2026, 7:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media

NCT03404531
View directory record Official record
Conditions
HIV Infections
Interventions
Social Media Messages Intervention Group, Website Only Group
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

NCT00001096
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes

NCT00001062
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

NCT00091741
View directory record Official record
Conditions
HIV Infection
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dipyridamole for Immune Activation in HIV

NCT02121756
View directory record Official record
Conditions
HIV Infection
Interventions
Dipyridamole, Placebo, then Dipyridamole
Drug
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 14, 2026, 7:43 PM EDT
Completed No phase listed Observational

Impact of Antiretroviral Therapy on Cardiac Biomarkers

NCT00641888
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 69 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)

NCT04519970
View directory record Official record
Conditions
Hiv
Interventions
Case Management
Behavioral
Lead sponsor
Gregory Huhn
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 14, 2026, 7:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons

NCT00996970
View directory record Official record
Conditions
Influenza, HIV Infections
Interventions
Not listed
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
3
States / cities
San Diego, California • Bethesda, Maryland • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants

NCT03934541
View directory record Official record
Conditions
HIV Infections
Interventions
MPER-656 Liposome Vaccine, Placebo for MPER-656 Liposome Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 14, 2026, 7:43 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

NCT00447902
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 14, 2026, 7:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
View directory record Official record
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 14, 2026, 7:43 PM EDT